Almax Pharma
ActiveSummary
Almax Pharma has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €303,429 and a net result of €2,070. Equity is growing by about 8.2% per year across the filed financial years. Its solvency ranks better than 93% of 22,632 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
History
Acts, filings and financial milestones
19-01
Gazette deed
Resignation: BROUSMICHE Christine Rita Thérèse (manager)Appointment: BROUSMICHE Christine Rita Thérèse (director) · Capital conversion · Reserve release12 facts ▸
- General meeting, “assemblée générale des actionnaires” (deed in French)
- Other provision, “application du Code des sociétés et des associations, société privée à responsabilité limitée” (deed in French)
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Reserve release, “limitation, compte de capitaux propres statutairement indisponible” (deed in French)
- Amendment of the articles
- Capital
- Power of attorney, Vincent BAELDEN
- Director resignation, BROUSMICHE Christine Rita Thérèse (manager)
- Director discharge, BROUSMICHE Christine Rita Thérèse
- Director appointment, BROUSMICHE Christine Rita Thérèse (director (not named in the articles))
- Registered office clause, “5651 Thy-le-Château,ville de Walcourt,Rue Saints Pierre et Paul,n°10, SIXIEME RESOLUTION : SIEGE” (deed in French)
- Power of attorney
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.